Professur für Endokrinologie

Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study (2021) Pavel ME, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Consensus on molecular imaging and theranostics in neuroendocrine neoplasms (2021) Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, et al. Journal article, Review article Advanced small intestine well-differentiated neuroendocrine tumors (WD-SiNET): A survey of practice on 3rd line treatment (2021) Lamarca A, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel ME, Alonso-Gordoa T Conference contribution The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors: Results from phase 3 of the RAISE project (2021) Pavel ME, Dromain C, Ronot M, Schaefer N, Mandair D, Gueguen D, Elvira D, et al. Conference contribution Dissociated response as a new biomarker of treatment response in neuroendocrine tumors: Results from phase 3 of the RAISE project (2021) Dromain C, Pavel ME, Ronot M, Schaefer N, Mandair D, Gueguen D, Cheng C, et al. Conference contribution Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era (2021) Rodriguez-Freixinos V, Capdevila J, Pavel ME, Thawer A, Baudin E, O'Toole D, Herrmann K, et al. Journal article, Review article Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America (2021) Kolarova T, Mcdonnell M, Bouvier CV, Pavel ME, Singh H, Howe J, Singh S, et al. Conference contribution Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials (2021) Fazio N, Carnaghi C, Buzzoni R, Valle JW, Herbst F, Ridolfi A, Strosberg J, et al. Journal article Spätfolgen nach Immuntherapie: Immunvermittelte Nebenwirkungen von Checkpointinhibitoren (2021) Duong SL, Zierold S, Kramer R, Reincke M, Kerl-French K, Boehmerle W, Pavel ME, et al. Journal article, Review article Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms (2020) Merola E, Dal Buono A, Denecke T, Arsenic R, Pape UF, Jann H, Wiedenmann B, Pavel ME Journal article